Povetacicept  (Synonyms: ALPN-303)

Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The K_d value of Povetacicept for human BAFF is 59.3 pM, while its K_d value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis^[1][2][3].

Human

TNFSF13B

Povetacicept (0.137-33.3 nM; 240-1800 s) binds to recombinant human APRIL with a K_d value of 1.00 pM, and also binds to recombinant human BAFF with a K_d value of 59.3 pM, exhibiting high-affinity dual binding activity toward these two cytokines^[2].
Povetacicept (2.5 pM-200 nM; 5 h) potently inhibits the signaling pathways of APRIL, BAFF, BAFF 60-mer and BAFF/APRIL heterotrimer in TACI/Jurkat/NF-κB reporter cells^[2].
Povetacicept (7 d) potently inhibits the proliferation of primary human B cells, the differentiation of class-switched memory B cells into plasma cells, and the secretion of immunoglobulins^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Povetacicept (10 mg/kg; i.p.; twice weekly; 3.5 weeks) significantly reduces bone marrow antibody-secreting cell counts, suppresses autoantibody production, and increases hematocrit in an HOD⁺OTII⁺ mouse model of AIHA^[1].
Povetacicept (15 mg/kg; i.p.; 2 doses (days 4 and 11)) potently reduces splenic immune cell subsets and inhibits T cell-dependent antibody formation more effectively than WT TACI-Fc comparators in KLH-immunized mice^[2].
Povetacicept (10 mg/kg; i.p.; 2 doses (days 1 and 6)) exhibits superior immunosuppressive activity over single-target inhibitors, combination therapy, telitacicept, and anti-CD20 in SRBC-immunized mice, leading to greater suppression of T cell-dependent antibody responses^[2].
Povetacicept (17 mg/kg; i.p.; twice weekly; 20 weeks) significantly suppresses lupus disease activity, improves survival, and reduces renal and glandular pathology in the spontaneous NZB/NZW F1 lupus mouse model^[2].
Povetacicept (10 mg/kg; i.p.; twice weekly; day 5 to day 88) significantly suppresses renal immune deposition and reduces pathogenic splenic immune cell subsets in the inducible bm12 lupus mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

62.61 kDa

2490217-42-8

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  FPIA_[PROTEIN_1REPEAT]2-FC

• 
  Immobilized APRIL/TNFSF13 Trimer Protein, Human (HEK293, His-Flag, HY-P70733A) can bind Povetacicept. The EC₅₀ for this effect is 2.624 ng/mL.

• [1]. Stacey Dillon, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front. Immunol., 06 June 2025.

  [2]. Evans LS, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023;75(7):1187-1202.  [Content Brief]

  [3]. Rinaldi E, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front Immunol. 2025;16:1533093. Published 2025 Jun 6.  [Content Brief]